OncoCyte (NASDAQ:OCX) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX) in a research report sent to investors on Wednesday morning. The brokerage issued a sell rating on the stock.

Several other brokerages have also recently issued reports on OCX. Stephens reissued an equal weight rating and issued a $4.00 price objective on shares of OncoCyte in a research note on Wednesday, April 17th. Benchmark reissued a speculative buy rating and issued a $5.00 price objective on shares of OncoCyte in a research note on Monday, April 15th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, OncoCyte has an average rating of Hold and an average target price of $4.06.

OncoCyte Price Performance

OCX opened at $2.46 on Wednesday. The stock’s 50 day moving average price is $2.92 and its 200-day moving average price is $3.04. OncoCyte has a one year low of $2.08 and a one year high of $6.20.

Insiders Place Their Bets

In related news, major shareholder Broadwood Partners, L.P. bought 2,420,000 shares of the stock in a transaction on Thursday, April 11th. The stock was bought at an average price of $2.92 per share, for a total transaction of $7,066,400.00. Following the completion of the acquisition, the insider now directly owns 4,929,066 shares in the company, valued at $14,392,872.72. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other OncoCyte news, Director Andrew Arno acquired 33,898 shares of the firm’s stock in a transaction dated Thursday, April 11th. The stock was purchased at an average price of $2.95 per share, for a total transaction of $99,999.10. Following the acquisition, the director now owns 69,054 shares in the company, valued at approximately $203,709.30. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Broadwood Partners, L.P. acquired 2,420,000 shares of the firm’s stock in a transaction dated Thursday, April 11th. The shares were acquired at an average price of $2.92 per share, with a total value of $7,066,400.00. Following the acquisition, the insider now owns 4,929,066 shares in the company, valued at approximately $14,392,872.72. The disclosure for this purchase can be found here. Insiders purchased a total of 2,457,288 shares of company stock worth $7,176,400 over the last 90 days. Company insiders own 1.94% of the company’s stock.

OncoCyte Company Profile

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.